ClinicaliQ Trial Snapshot
- Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren’s Syndrome — Active Not Recruiting • Phase III • NCT05349214.
- Trial testing whether ianalumab improves symptoms and safety in people with active Sjögren's syndrome compared to placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2) Conditions: Sjogren Syndrome Interventions: VAY736, Placebo Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 506 participants